Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients With Hyperuricemia

NCT04040816 is registered in ClinicalTrials.gov with Shanton Pharma Co., Ltd. as lead sponsor.

NCT NCT04040816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04040816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients With Hyperuricemia
Lead sponsor
Shanton Pharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2019
Completion date
August 30, 2020
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gout, hyperuricemia